Literature DB >> 25445453

Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength.

A Morse1, N Y C Yu2, L Peacock3, K Mikulec4, I Kramer5, M Kneissel6, M M McDonald7, D G Little8.   

Abstract

Sclerostin deficiency, via genetic knockout or anti-Sclerostin antibody treatment, has been shown to cause increased bone volume, density and strength of calluses following endochondral bone healing. However, there is limited data on the effect of Sclerostin deficiency on the formative early stage of fibrocartilage (non-bony tissue) formation and removal. In this study we extensively investigate the early fibrocartilage callus. Closed tibial fractures were performed on Sost(-/-) mice and age-matched wild type (C57Bl/6J) controls and assessed at multiple early time points (7, 10 and 14days), as well as at 28days post-fracture after bony union. External fixation was utilized, avoiding internal pinning and minimizing differences in stability stiffness, a variable that has confounded previous research in this area. Normal endochondral ossification progressed in wild type and Sost(-/-) mice with equivalent volumes of fibrocartilage formed at early day 7 and day 10 time points, and bony union in both genotypes by day 28. There were no significant differences in rate of bony union; however there were significant increases in fibrocartilage removal from the Sost(-/-) fracture calluses at day 14 suggesting earlier progression of endochondral healing. Earlier bone formation was seen in Sost(-/-) calluses over wild type with greater bone volume at day 10 (221%, p<0.01). The resultant Sost(-/-) united bony calluses at day 28 had increased bone volume fraction compared to wild type calluses (24%, p<0.05), and the strength of the fractured Sost(-/-) tibiae was greater than that that of wild type fractured tibiae. In summary, bony union was not altered by Sclerostin deficiency in externally-fixed closed tibial fractures, but fibrocartilage removal was enhanced and the resultant united bony calluses had increased bone fraction and increased strength. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone; Endochondral; Fracture; Repair; Sclerostin; Sost

Mesh:

Substances:

Year:  2014        PMID: 25445453     DOI: 10.1016/j.bone.2014.10.018

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  13 in total

1.  CORR Insights(®): Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?

Authors:  Nilsson Holguin
Journal:  Clin Orthop Relat Res       Date:  2016-01-12       Impact factor: 4.176

Review 2.  Mechanisms Underlying Normal Fracture Healing and Risk Factors for Delayed Healing.

Authors:  Cheng Cheng; Dolores Shoback
Journal:  Curr Osteoporos Rep       Date:  2019-02       Impact factor: 5.096

Review 3.  The Role of the Osteocyte in Bone and Nonbone Disease.

Authors:  Lynda F Bonewald
Journal:  Endocrinol Metab Clin North Am       Date:  2016-12-12       Impact factor: 4.741

4.  The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.

Authors:  Heather Fairfield; Carolyne Falank; Elizabeth Harris; Victoria Demambro; Michelle McDonald; Jessica A Pettitt; Sindhu T Mohanty; Peter Croucher; Ina Kramer; Michaela Kneissel; Clifford J Rosen; Michaela R Reagan
Journal:  J Cell Physiol       Date:  2017-06-06       Impact factor: 6.384

5.  Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?

Authors:  Mohammad M Alzahrani; Frank Rauch; Reggie C Hamdy
Journal:  Clin Orthop Relat Res       Date:  2015-11-25       Impact factor: 4.176

6.  Triweekly administration of parathyroid hormone (1-34) accelerates bone healing in a rat refractory fracture model.

Authors:  Yohei Kumabe; Sang Yang Lee; Takahiro Waki; Takashi Iwakura; Shunsuke Takahara; Michio Arakura; Yu Kuroiwa; Tomoaki Fukui; Tomoyuki Matsumoto; Takehiko Matsushita; Kotaro Nishida; Ryosuke Kuroda; Takahiro Niikura
Journal:  BMC Musculoskelet Disord       Date:  2017-12-21       Impact factor: 2.362

7.  The Microdamage and Expression of Sclerostin in Peri-implant Bone under One-time Shock Force Generated by Impact.

Authors:  Xiaoou Diao; Zhirui Li; Baili An; Haitao Xin; Yulu Wu; Kai Li; Fan Feng; Chenyun Dou
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

8.  Reduction of SOST gene promotes bone formation through the Wnt/β-catenin signalling pathway and compensates particle-induced osteolysis.

Authors:  Zai Hang Zhang; Xin Yu Jia; Jing Yi Fang; Hao Chai; Qun Huang; Chang She; Peng Jia; De Chun Geng; Wei Xu
Journal:  J Cell Mol Med       Date:  2020-03-05       Impact factor: 5.310

Review 9.  Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.

Authors:  Claire MacNabb; D Patton; J S Hayes
Journal:  J Osteoporos       Date:  2016-05-26

Review 10.  Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review.

Authors:  Pui Kit Suen; Ling Qin
Journal:  J Orthop Translat       Date:  2015-09-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.